Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study

Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma

(2013) G Srivastava et al.   LEUKEMIA

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project

(2012) H Avet-Loiseau et al.   LEUKEMIA

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Phase II Trial of Combination Therapy With Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Myeloma

(2009) Andrzej J. Jakubowiak et al.   JOURNAL OF CLINICAL ONCOLOGY

Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy

(2009) Paul G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study

(2009) Ingemar Turesson et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)

(2009) E Kastritis et al.   LEUKEMIA